Friday, March 13, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

CDC significantly cuts estimate of omicron’s prevalence in US

The Centers for Disease Control and Prevention (CDC) significantly revised downward the estimate of the percentage of new COVID-19 infections in the U.S. caused by the omicron variant of the virus.

According to agency data, omicron accounted for about 59 percent of all U.S. infections as of Dec. 25. Previously, the CDC said the omicron variant comprised 73 percent of all cases for the week ending Dec. 18. But that number has now been revised to 22.5 percent of all cases.

The omicron variant is highly transmissible and spreading rapidly, resulting in surges of infections even among people who are vaccinated. However, people who are vaccinated, and especially those who have received booster shots, are well protected against severe disease from the variant, experts say, meaning it poses the greatest risk to the unvaccinated.

Source: The Hill

https://thehill.com/policy/healthcare/587506-cdc-lowers-estimate-of-omicron-prevalence-in-us

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

2027 Medicare Advantage & Part D Advance Notice

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!